GOTHENBURG, Sweden, February 18 2020 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL) today announced that the first patient in Japan has initiated treatment in the global Phase 3 AGENT study.
Month: February 2020
Our CEO, Dr. Ulf Jungnelius, was featured on Karen Jagoda’s empowered patient podcast to discuss colorectal cancer and how our drug, arfolitixorin, has the potential to improve the efficacy of standard of care chemotherapy for patients. Ulf additionally provides updates on our ongoing Global Phase 3 AGENT study. Listen to the full episode here >>